Fig. 5. Summary of transgenic analysis of the wild-type TrkA minimal enhancer and TrkA minimal enhancers with one or both Brn3a-binding-site mutations. Note that the minimal enhancer that contains both Brn3a-binding-site mutations has apparently reduced activity in trigeminal ganglia. *The reported numbers include results from three stable TrkA-minimal-enhancer transgenic lines.